GENFIT Explores Long-Term Prospects for MASH Diagnostic Technology

GENFIT has underscored the commercial viability of its MASH diagnostics technology, targeting a large pool of nearly 90 million individuals in the U.S. This technology offers simple, reliable blood-based testing for Metabolic dysfunction-Associated SteatoHepatitis (MASH), a significant advancement amidst expanding therapeutic options in the field. IQVIA projects that products incorporating this technology could reach peak U.S. sales exceeding $1.5 billion by 2033, positioning GENFIT for substantial royalty-based revenue.

U.S. peak sales could surpass $1.5 billion by 2033, thanks to expanding reimbursement policies, enhanced integration into clinical guidelines, and increased awareness fostered by pharmaceutical firms. Diagnostics are poised to gain momentum post-2028 as adequate physician education and patient identification drive demand. GENFIT aims to enhance market presence not only in the U.S. but also across Europe and Asia, where similar expansion strategies are anticipated.